CoChat

Effects of Enteric Environmental Modification by Coffee Components on Neurodegeneration in Rotenone-Treated Mice

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Epidemiological studies have shown that coffee consumption decreases the risk of Parkinson’s disease (PD). Caffeic acid (CA) and chlorogenic acid (CGA) are coffee components that have antioxidative properties. Rotenone, a mitochondrial complex I inhibitor, has been used to develop parkinsonian models, because the toxin induces PD-like pathology. Here, we examined the neuroprotective effects of CA and CGA against the rotenone-induced degeneration of central dopaminergic and peripheral enteric neurons. Male C57BL/6J mice were chronically administered rotenone (2.5 mg/kg/day), subcutaneously for four weeks. The animals were orally administered CA or CGA daily for 1 week before rotenone exposure and during the four weeks of rotenone treatment. Administrations of CA or CGA prevented rotenone-induced neurodegeneration of both nigral dopaminergic and intestinal enteric neurons. CA and CGA upregulated the antioxidative molecules, metallothionein (MT)-1,2, in striatal astrocytes of rotenone-injected mice. Primary cultured mesencephalic or enteric cells were pretreated with CA or CGA for 24 h, and then further co-treated with a low dose of rotenone (1–5 nM) for 48 h. The neuroprotective effects and MT upregulation induced by CA and CGA in vivo were reproduced in cultured cells. Our data indicated that intake of coffee components, CA and CGA, enhanced the antioxidative properties of glial cells and prevents rotenone-induced neurodegeneration in both the brain and myenteric plexus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells8030221

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Administrations of CA or CGA prevented degeneration of dopaminergic neurons in the SNpc of rotenone-treated mice. (A) Schematic illustration of the experimental protocol. Male C57BL/6J mice were injected subcutaneously with rotenone (2.5 mg/kg/day) for four weeks using an osmotic mini pump. Mice were orally administered CA (30 mg/kg/day) or CGA (50 mg/kg/day), dissolved in 5% methylcellulose, daily for one week before rotenone exposure, and then 5 days/week during the four weeks of rotenone treatment. (B) Representative photomicrographs of immunohistochemistry for TH in the SNpc of rotenone-treated mice after treatment with CA or CGA. Scale bar = 200 µm. (C) Changes in the number of TH-positive nigral neurons after administration of CA or CGA. Each value is the mean ± SEM (n = 6–7). ** p < 0.01 vs. the vehicle-treated control group, # p < 0.05, ## p < 0.01 between the two indicated groups.
Figure 1 Administrations of CA or CGA prevented degeneration of dopaminergic neurons in the SNpc of rotenone-treated mice. (A) Schematic illustration of the experimental protocol. Male C57BL/6J mice were injected subcutaneously with rotenone (2.5 mg/kg/day) for four weeks using an osmotic mini pump. Mice were orally administered CA (30 mg/kg/day) or CGA (50 mg/kg/day), dissolved in 5% methylcellulose, daily for one week before rotenone exposure, and then 5 days/week during the four weeks of rotenone treatment. (B) Representative photomicrographs of immunohistochemistry for TH in the SNpc of rotenone-treated mice after treatment with CA or CGA. Scale bar = 200 µm. (C) Changes in the number of TH-positive nigral neurons after administration of CA or CGA. Each value is the mean ± SEM (n = 6–7). ** p < 0.01 vs. the vehicle-treated control group, # p < 0.05, ## p < 0.01 between the two indicated groups.CC BY · PubMed Central
Figure 2 Effects of CA or CGA administrations on astrocytic MT-1,2 expression in the striatum of rotenone-treated mice. (A) Representative photomicrographs of MT-1,2 and S100β double immunostaining in the striatum of rotenone (2.5 mg/kg/day)-treated mice after treatment with CA (30 mg/kg/day) or CGA (50 mg/kg/day). Green: S100β-positive astrocytes. Red: MT-1,2-positive cells. Blue: nuclear staining with Hoechst 33342. Solid arrowheads: MT-1,2-positive astrocytes. Scale bar = 50 µm. (B,C) Quantitation of MT-1,2 and S100β expression in the striatum of rotenone-treated mice after treatment with CA or CGA. (B) Number of immunopositive cells, (C) proportion of MT-1,2-positive cells/S100β-positive cells. Data are means ± SEM (n = 6–7). # p < 0.05, ## p < 0.01 vs. the rotenone-treated group.
Figure 2 Effects of CA or CGA administrations on astrocytic MT-1,2 expression in the striatum of rotenone-treated mice. (A) Representative photomicrographs of MT-1,2 and S100β double immunostaining in the striatum of rotenone (2.5 mg/kg/day)-treated mice after treatment with CA (30 mg/kg/day) or CGA (50 mg/kg/day). Green: S100β-positive astrocytes. Red: MT-1,2-positive cells. Blue: nuclear staining with Hoechst 33342. Solid arrowheads: MT-1,2-positive astrocytes. Scale bar = 50 µm. (B,C) Quantitation of MT-1,2 and S100β expression in the striatum of rotenone-treated mice after treatment with CA or CGA. (B) Number of immunopositive cells, (C) proportion of MT-1,2-positive cells/S100β-positive cells. Data are means ± SEM (n = 6–7). # p < 0.05, ## p < 0.01 vs. the rotenone-treated group.CC BY · PubMed Central
Figure 3 Administrations of CA or CGA prevented the degeneration of enteric neurons in the intestinal myenteric plexus of rotenone-treated mice. (A) Representative photomicrographs of immunohistochemistry for β-tubulin III in the intestine of mice. Green: β-tubulin III-positive neurons. Blue: nuclear staining with Hoechst 33342. Scale bar = 50 µm. (B) Representative photomicrographs of β-tubulin III-positive neurons in the intestine of rotenone-treated mice after treatment with CA (30 mg/kg/day) or CGA (50 mg/kg/day). Scale bar = 50 µm. (C,D) Quantitation of β-tubulin III-positive signals in the intestine. (C) Area of β-tubulin III-positive myenteric plexus, (D) integrated density of β-tubulin III immunoreactivity. Data are means ± SEM (n = 6–7). *** p < 0.001 vs. the vehicle-treated control group, ### p < 0.001 between the two indicated groups.
Figure 3 Administrations of CA or CGA prevented the degeneration of enteric neurons in the intestinal myenteric plexus of rotenone-treated mice. (A) Representative photomicrographs of immunohistochemistry for β-tubulin III in the intestine of mice. Green: β-tubulin III-positive neurons. Blue: nuclear staining with Hoechst 33342. Scale bar = 50 µm. (B) Representative photomicrographs of β-tubulin III-positive neurons in the intestine of rotenone-treated mice after treatment with CA (30 mg/kg/day) or CGA (50 mg/kg/day). Scale bar = 50 µm. (C,D) Quantitation of β-tubulin III-positive signals in the intestine. (C) Area of β-tubulin III-positive myenteric plexus, (D) integrated density of β-tubulin III immunoreactivity. Data are means ± SEM (n = 6–7). *** p < 0.001 vs. the vehicle-treated control group, ### p < 0.001 between the two indicated groups.CC BY · PubMed Central
Figure 4 Effects of CA or CGA administrations on enteric glial cells in the intestines of rotenone-treated mice. (A) Representative photomicrographs of immunohistochemistry for GFAP in the intestines of rotenone-treated mice after treatment with CA (30 mg/kg/day) or CGA (50 mg/kg/day). Scale bar = 50 µm. (B,C) Quantitation of GFAP-positive signals in the intestine of mice. (B) Area of GFAP-positive signal, (C) integrated density of GFAP immunoreactivity. Data are means ± SEM (n = 6–7). * p < 0.05, *** p < 0.001 vs. the vehicle-treated control group.
Figure 4 Effects of CA or CGA administrations on enteric glial cells in the intestines of rotenone-treated mice. (A) Representative photomicrographs of immunohistochemistry for GFAP in the intestines of rotenone-treated mice after treatment with CA (30 mg/kg/day) or CGA (50 mg/kg/day). Scale bar = 50 µm. (B,C) Quantitation of GFAP-positive signals in the intestine of mice. (B) Area of GFAP-positive signal, (C) integrated density of GFAP immunoreactivity. Data are means ± SEM (n = 6–7). * p < 0.05, *** p < 0.001 vs. the vehicle-treated control group.CC BY · PubMed Central
Figure 5 Neuroprotective effects of CA and CGA against rotenone-induced dopaminergic neurotoxicity in cultured mesencephalic cells. (A) Schematic illustration of the experimental protocol. Mesencephalic neuronal and astrocyte co-cultures were pretreated with CA (10 or 25 µM) or CGA (25 µM) for 24 h and co-treated with rotenone (1–5 nM) for a further 48 h. (B,C) Changes in the number of TH-positive neurons after treatment with rotenone and CA (B) or CGA (C). Data are means ± SEM (n = 4). *** p < 0.001 vs. each control group, ## p < 0.01, ### p < 0.001 between the two indicated groups.
Figure 5 Neuroprotective effects of CA and CGA against rotenone-induced dopaminergic neurotoxicity in cultured mesencephalic cells. (A) Schematic illustration of the experimental protocol. Mesencephalic neuronal and astrocyte co-cultures were pretreated with CA (10 or 25 µM) or CGA (25 µM) for 24 h and co-treated with rotenone (1–5 nM) for a further 48 h. (B,C) Changes in the number of TH-positive neurons after treatment with rotenone and CA (B) or CGA (C). Data are means ± SEM (n = 4). *** p < 0.001 vs. each control group, ## p < 0.01, ### p < 0.001 between the two indicated groups.CC BY · PubMed Central
Figure 6 Effects of treatment with CA or CGA followed by rotenone exposure on MT-1,2 expression in mesencephalic astrocyte cultures. Astrocyte cultures were pretreated with CA (10 or 25 µM) or CGA (25 µM) for 24 h and co-treated with rotenone (1–5 nM) for a further 48 h. (A) Representative photomicrographs of MT-1,2 and GFAP double immunostaining in astrocyte cultures. Red: MT-1,2-positive signals. Green: GFAP-positive astrocytes. Blue: nuclear staining with Hoechst 33342. Scale bar = 50 µm. (B,C) Quantitation of MT-1,2-positive signals in astrocyte cultures after treatment with rotenone and CA (B) or CGA (C). Each value is the mean ± SEM (n = 8–13) expressed as the percentage of the MT-1,2-immunopositive astrocytes in the total cell population. *** p < 0.001 vs. each control group, # p < 0.05, ### p < 0.001 between the two indicated groups.
Figure 6 Effects of treatment with CA or CGA followed by rotenone exposure on MT-1,2 expression in mesencephalic astrocyte cultures. Astrocyte cultures were pretreated with CA (10 or 25 µM) or CGA (25 µM) for 24 h and co-treated with rotenone (1–5 nM) for a further 48 h. (A) Representative photomicrographs of MT-1,2 and GFAP double immunostaining in astrocyte cultures. Red: MT-1,2-positive signals. Green: GFAP-positive astrocytes. Blue: nuclear staining with Hoechst 33342. Scale bar = 50 µm. (B,C) Quantitation of MT-1,2-positive signals in astrocyte cultures after treatment with rotenone and CA (B) or CGA (C). Each value is the mean ± SEM (n = 8–13) expressed as the percentage of the MT-1,2-immunopositive astrocytes in the total cell population. *** p < 0.001 vs. each control group, # p < 0.05, ### p < 0.001 between the two indicated groups.CC BY · PubMed Central
Figure 7 Neuroprotective effects of CA and CGA against rotenone-induced enteric neurotoxicity in primary cultured intestinal cells. (A) Schematic illustration of the experimental protocol. Enteric neuronal and glial co-cultures were pretreated with CA (10 or 25 µM) or CGA (25 µ) for 24 h and co-treated with rotenone (1–5 nM) for further 48 h. (B) Localization of β-tubulin III- and GFAP-positive signals. Red: β-tubulin III-positive enteric neuronal cells. Green: GFAP-positive enteric glial cells. Blue: nuclear staining with Hoechst 33342. Scale bar = 50 µm. (C) Representative photomicrographs of immunohistochemistry for β-tubulin III and GFAP in enteric cell cultures after treatment with rotenone (5 nM) and CA (25 µM) or CGA (25 µM). Red: β-tubulin III-positive enteric neuronal cells. Green: GFAP-positive enteric glial cells. Blue: nuclear staining with Hoechst 33342. Scale bar = 100 µm. (D,E) Quantitation of β-tubulin III-positive signals in enteric cell cultures after treatment with rotenone and CA (D) or CGA (E). Data are means ± SEM (n = 3–6). ** p < 0.01, *** p < 0.001 vs. each control group; # p < 0.05, ## p < 0.01, ### p < 0.001 between the two indicated groups.
Figure 7 Neuroprotective effects of CA and CGA against rotenone-induced enteric neurotoxicity in primary cultured intestinal cells. (A) Schematic illustration of the experimental protocol. Enteric neuronal and glial co-cultures were pretreated with CA (10 or 25 µM) or CGA (25 µ) for 24 h and co-treated with rotenone (1–5 nM) for further 48 h. (B) Localization of β-tubulin III- and GFAP-positive signals. Red: β-tubulin III-positive enteric neuronal cells. Green: GFAP-positive enteric glial cells. Blue: nuclear staining with Hoechst 33342. Scale bar = 50 µm. (C) Representative photomicrographs of immunohistochemistry for β-tubulin III and GFAP in enteric cell cultures after treatment with rotenone (5 nM) and CA (25 µM) or CGA (25 µM). Red: β-tubulin III-positive enteric neuronal cells. Green: GFAP-positive enteric glial cells. Blue: nuclear staining with Hoechst 33342. Scale bar = 100 µm. (D,E) Quantitation of β-tubulin III-positive signals in enteric cell cultures after treatment with rotenone and CA (D) or CGA (E). Data are means ± SEM (n = 3–6). ** p < 0.01, *** p < 0.001 vs. each control group; # p < 0.05, ## p < 0.01, ### p < 0.001 between the two indicated groups.CC BY · PubMed Central
Figure 8 Treatment with CA or CGA inhibits rotenone-induced MT downregulation in the enteric glial cells. Enteric neuronal and glial co-cultures were pretreated with CA (10 or 25 µM) or CGA (25 µM) for 24 h and co-treated with rotenone (1–5 nM) for a further 48 h. (A) Representative photomicrographs of immunohistochemistry for MT-1,2 and GFAP in enteric cell cultures after treatment with rotenone (5 nM) and CA (25 µM) or CGA (25 µM). Red: MT-1,2-positive signals. Green: GFAP-positive enteric glial cells. Blue: nuclear staining with Hoechst 33342. Scale bar = 100 µm. (B,C) Quantitation of MT-1,2-positive signals in the enteric cell cultures after treatment with rotenone and CA (B) or CGA (C). Data are means ± SEM (n = 3–8). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. each control group; # p < 0.05, ### p < 0.001 between the two indicated groups.
Figure 8 Treatment with CA or CGA inhibits rotenone-induced MT downregulation in the enteric glial cells. Enteric neuronal and glial co-cultures were pretreated with CA (10 or 25 µM) or CGA (25 µM) for 24 h and co-treated with rotenone (1–5 nM) for a further 48 h. (A) Representative photomicrographs of immunohistochemistry for MT-1,2 and GFAP in enteric cell cultures after treatment with rotenone (5 nM) and CA (25 µM) or CGA (25 µM). Red: MT-1,2-positive signals. Green: GFAP-positive enteric glial cells. Blue: nuclear staining with Hoechst 33342. Scale bar = 100 µm. (B,C) Quantitation of MT-1,2-positive signals in the enteric cell cultures after treatment with rotenone and CA (B) or CGA (C). Data are means ± SEM (n = 3–8). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. each control group; # p < 0.05, ### p < 0.001 between the two indicated groups.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 53

Metadata

Authors
Miyazaki, I., Isooka, N., Wada, K., Kikuoka, R., Kitamura, Y., & Asanuma, M.
Affiliations
Okayama University (JP)
Corresponding author
Miyazaki, Ikuko
Venue
Cells
Publisher
MDPI AG
Published
2019-03-07
Volume
8
Issue
3
Pages
221
ISSN
2073-4409 (ISSN-L)
OpenAlex
W2919600163
Cited by
53
References
50
Citations by year
2026: 3 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 8 · 2020: 10 · 2019: 1
FWCI
4.72
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • All Japan Coffee Association (2016, 2018)
  • Japan Society for the Promotion of Science (JP25461279, JP16K09673)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
caffeic acid, chlorogenic acid, rotenone, Parkinson's disease, neuroprotection, neurodegeneration, dopaminergic neurons, enteric neurons, myenteric plexus, metallothionein, astrocytes, oxidative stress, antioxidant activity, mitochondrial complex I inhibitors, glial cells
MeSH terms
Animals, Astrocytes, Caffeic Acids, Chlorogenic Acid, Coffee, Intestines, Male, Mesencephalon, Metallothionein, Mice, Inbred C57BL, Myenteric Plexus, Nerve Degeneration, Neuroglia, Rotenone, Down-Regulation, Up-Regulation, Neostriatum, Rats, Sprague-Dawley, Enteric Nervous System, Neuroprotective Agents, Dopaminergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.